



Coronary flow velocity reserve and inflammatory
markers in living kidney donors
Radhakrishnan, Ashwin; Price, Anna; Pickup, Luke; Law, Jonathan; McGee, Kirsty; Fabritz,




Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Radhakrishnan, A, Price, A, Pickup, L, Law, J, McGee, K, Fabritz, L, Senior, R, Steeds, R, Ferro, C & Townend,
J 2020, 'Coronary flow velocity reserve and inflammatory markers in living kidney donors', International Journal
of Cardiology, vol. 320, pp. 141-147. https://doi.org/10.1016/j.ijcard.2020.08.013
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 11. May. 2021
International Journal of Cardiology xxx (2020) xxx
IJCA-28801; No of Pages 7
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdCoronary flow velocity reserve and inflammatory markers in living
kidney donorsAshwin Radhakrishnan a,b,⁎, Anna M. Price a,c, Luke C. Pickup a,b, Jonathan P. Lawa,c, Kirsty C. McGee d,
Larissa Fabritz b,e, Roxy Senior f,g, Richard P. Steeds a,b, Charles J. Ferro a,c, Jonathan N. Townend a,b
a Birmingham Cardio-Renal Group, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
b Department of Cardiology, Queen Elizabeth Hospital, Birmingham, United Kingdom
c Department of Nephrology, Queen Elizabeth Hospital, Birmingham, United Kingdom
d Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom
e Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
f Cardiac Research Unit, Northwick Park Hospital, London, United Kingdom
g Department of Cardiology, Royal Brompton Hospital, London, United KingdomAbbreviations: BP, Blood pressure; CAD, Coronary art
reserve; CFVR, Coronary flow velocity reserve; CFV,
Chronic kidney disease; CMD, Coronary microvascular dy
Renal Impairment in Birmingham - Donor study; CRIB-FL
in Birmingham Coronary FLOW Reserve study; CR
Electrocardiogram; eGFR, Estimated glomerular filtration r
tor antagonist; IL-6, Interleukin-6; IL-8, Interleukin-8; hs
peptide; LKD, Living kidney donors; LVH, Left ventricular
contrast echocardiogram; MI, Mechanical index; S
Sympathetic nervous system; TNFα, Tumour necrosis fac
cardiogram; QEHB, Queen Elizabeth Hospital Birmingham
⁎ Corresponding author at: Department of Cardiology, N
Hospital, Edgbaston, Birmingham B15 2TH, United Kingdo
E-mail address: a.radhakrishnan@nhs.net (A. Radhakr
https://doi.org/10.1016/j.ijcard.2020.08.013
0167-5273/© 2020 The Authors. Published by Elsevier B.V
Please cite this article as: A. Radhakrishnan
kidney donors, International Journal of Carda b s t r a c ta r t i c l e i n f oArticle history:
Received 24 May 2020
Received in revised form 3 July 2020





Coronary flow velocity reserve
InflammationBackground: Coronarymicrovascular dysfunction is prevalent in chronic kidney disease (CKD), andmay contrib-
ute to the development of myocardial dysfunction in CKD. Coronary flow velocity reserve (CFVR) is a marker of
coronary microvascular function and falls with increasing CKD stage. Living kidney donors have renal function
consistent with early stage CKD and concern has been raised about their cardiovascular risk. No studies to date
have investigated the presence of coronary microvascular dysfunction in living kidney donors.
Methods: 25 healthy controls and 23 living kidney donors were recruited and underwent assessment with trans-
thoracic echocardiography, Doppler CFVR,myocardial contrast echocardiography and serummultiplex immuno-
assay panels.
Results: Doppler CFVR was significantly reduced in living kidney donors compared to controls (mean CFVR
3.4 ± 0.7 vs 3.8 ± 0.6, mean difference 0.4 95% confidence interval 0.03–0.8, p =.036). Quantitative myo-
cardial contrast echocardiography showed a trend towards reduced coronary flow reserve in living kidney
donors. Compared to controls, living kidney donors had higher serum high sensitivity C reactive peptide
(hsCRP) and lower levels of uromodulin.
Conclusions: This is the first study of CFVR in living kidney donors. We have shown that the modest drop in
estimated glomerular filtration rate in living kidney donors is associated with lower values of Doppler CFVR
compared to controls, suggesting that isolated reductions in renal function may lead to altered microvascu-
lar function. The increase in hsCRP and reduction in uromodulin suggests that chronic subclinical inflam-
mation may contribute to altered microvascular function in this population.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).ery disease; CFR, Coronary flow
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Kidney transplantation is the most effective form of renal replace-
ment therapy and is associated with significant health benefits for the
recipient, including improved blood pressure (BP) control, and reduced
all-cause and cardiovascular mortality [1]. Given the shortage of cadav-
eric donors, there is a worldwide drive to increase rates of living kidney
donation, which now accounts for approximately 30% of transplants in
the United Kingdom (UK) [2]. Living kidney donors (LKD) provide a
unique model of reduced estimated glomerular filtration rate (eGFR)
without progressive kidney disease or confounding comorbidities.
After unilateral nephrectomy, most donors will have an eGFR consis-
tent with stage 2–3 chronic kidney disease (CKD) [3]. Although long
term evidence shows that living kidney donation is safe, the possiblethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
, Coronary flow velocity reserve and inflammatory markers in living
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2 A. Radhakrishnan et al. / International Journal of Cardiology xxx (2020) xxxcardiovascular risks of living kidney donation remain unclear. Previ-
ous studies of LKD have shown small but significant changes in car-
diovascular structure and function at 1 year after donation [4,5].
Although the majority of studies, including a recent meta-analysis,
have not shown any increased mortality compared to the general
population [6,7], Mjoen et al raised concerns about long term mor-
tality in LKD when compared to a highly selected control group
who met the eligibility criteria for living kidney donation [8].
There is growing interest in the role that coronary microvascular
dysfunction (CMD) may play in the increased cardiovascular risk seen
in CKD [9]. Coronary flow reserve (CFR) is a widely reported parameter
ofmicrovascular function and is primarily ameasure of the ability of the
microcirculation to respond to vasodilatory stimuli. In normal subjects,
coronary flow should at least double with hyperaemia, so a CFR <2 is
considered abnormal [9]. Multiple studies have shown a graded inverse
relationship between CFR and CKD stage, and this has prognostic signif-
icance [9–14]. Both CFR and its surrogate marker CFVR (coronary flow
velocity reserve) can be reliably measured using non-invasive contrast
enhanced echocardiography techniques [15–17].
Reduced CFR is seen even in early CKD (stages 1–3), a level of eGFR
often present in LKD [10–12]. Given the increasing numbers of LKD
worldwide, it is important to assess whether unilateral nephrectomy
is associated with impaired microvascular function, which may have
long term implications for cardiovascular risk in donors. The Chronic
Renal Impairment in Birmingham Coronary Flow Reserve (CRIB-
FLOW) study was designed to assess coronary microvascular function




BetweenMay2019 and February 2020, 23 LKD and 25healthy controls
were enrolled in the CRIB-FLOW study at the Queen Elizabeth Hospital,
Birmingham (QEHB) – Supplementary Fig. 1. Participants were >18 years
of age and provided written informed consent. The study was carried out
in accordance with the principles of the Declaration of Helsinki. Donors
were recruited fromthe LKD registry atQEHB.Healthy controls, of a similar
age and gender, were recruited from staff members and control subjects
from the Chronic Renal Impairment in Birmingham – Donor (CRIB-
Donor) study [4].
Kidney donorswere>12months post-donation. Healthy controls had
eGFR >90ml/min/1.73m2 or eGFR 60-90ml/min/1.73m2 and no signifi-
cant proteinuria or signs of kidney damage. The Chronic Kidney Disease
Epidemiology Collaboration formula was used to calculate eGFR [18]. Ex-
clusion criteria were: pregnancy, diabetes mellitus, uncontrolled hyper-
tension, ischaemic heart disease, moderate/severe valvular heart disease
and contraindication to adenosine or sulfur hexafluoride contrast agent
(SonoVue, Bracco, Milan, Italy). The study was reviewed and approved
by the West Midlands – Solihull Research Ethics Committee (19/WM/
0066) and registered with ClinicalTrials.gov (NCT04014127).
2.2. Blood pressure
Supine and sitting office BP were measured using an automatic
BP monitor. The average of five readings taken over five minutes
was used.
2.3. Transthoracic echocardiography (TTE)
Two-dimensional echocardiography was performed by a single ex-
perienced cardiologist (AR) using a Philips iE33 machine (Philips, Eind-
hoven, Netherlands) with S5–1 transducer for TTE and myocardial
contrast echocardiogram (MCE) studies and S8–3 transducer for CFVR
measurements.Please cite this article as: A. Radhakrishnan, A.M. Price, L.C. Pickup, et al.
kidney donors, International Journal of Cardiology, https://doi.org/10.101Left ventricular mass was estimated using the Cube formula and
indexed for body surface area [19]. Left ventricular volumes and ejection
fraction were measured using the Simpson's biplane method [19]. Dia-
stolic function was quantified using multiple parameters [20]. Global
longitudinal strain was assessed in the 3 standard apical views using
speckle tracking.
2.4. Doppler coronary flow velocity reserve
Subjects were asked to abstain from caffeine for 24 hours prior to
the study. The left anterior descending artery (LAD) was identified on
colour Doppler in the anterior inter-ventricular sulcus using a modified
apical 2-chamber view (distal LAD) or a low parasternal short axis view
(mid LAD) as previously described [15]. Pulse wave Doppler signals of
LADflowwere recorded at rest and at hyperaemia,maintaining an iden-
tical probe position and angle. SonoVue was used, if needed, to identify
LAD flow and accentuate Doppler signals. Adenosine was infused, with
BP and electrocardiogram (ECG) monitoring, at a rate of 140micro-
grams/kg/min for 3 minutes to induce hyperaemia. Peak diastolic
coronary flow velocity (CFV) was calculated at rest and hyperaemia –
Supplementary Fig. 2. CFVR was calculated as hyperaemic CFV/rest
CFV. For each variable in the CFVR calculation, the highest values of 3
cardiac cycles were averaged.
2.5. Myocardial contrast echocardiography
Myocardial contrast echocardiography was performed as previ-
ously described [17]. Briefly, images were taken in the 3 standard
apical views using low-power continuous MCE at a mechanical
index (MI) of 0.1. SonoVue was infused at a rate of 70-100 ml/h
using an infusion pump that oscillates gently throughout the infu-
sion to ensure that microbubbles remain in suspension (Vueject,
Bracco, Milan, Italy). The infusion rate was adjusted to ensure ade-
quate myocardial opacification without attenuation. The focus was
set at the level of the mitral valve but moved towards the apex to
avoid near-field artefact. Triggered high MI (1.0) flash echocardiog-
raphy at end-systole was performed to destroy microbubbles in the
myocardium and to observe replenishment. End-systolic frames of
up to 10 cardiac cycles were captured in each view. Rest and adeno-
sine vasodilator stress images were recorded. Stress images were
reviewed for any regional wall motion abnormalities or any sub-
endocardial perfusion defects suggesting myocardial ischaemia.
2.6. Quantitative myocardial contrast echocardiography
The QLab system (Philips, Eindhoven, Netherlands) was used to
quantify MCE. The left ventricle was segmented using a 16-segment
model [19]. Regions of interest were placed across the entire thickness
of themyocardium in the 10mid and apical segments, taking care to ex-
clude the high-intensity endocardial and epicardial borders. Basal seg-
ments were excluded due to high rates of artefact. Segments were also
excluded if there was artefact, inadequate microbubble destruction, at-
tenuation, or a wide variation in contrast intensity. A minimum of 6
quantifiable segments was necessary for the study to be included in
analysis.
The QLab software automatically generated background-
subtracted plots of contrast intensity vs time which were fitted to
an exponential function y = A(1− e− βt). From this, peak myocar-
dial contrast intensity (A - representing myocardial blood volume)
and the slope of the replenishment curve (β - depicting mean
microbubble velocity) could be derived. The product of Axβ equals
myocardial blood flow (MBF). LAD MBF (average of mid
anteroseptal, apical septal, mid anterior and apical anterior seg-
ments) and global MBF (average of all ten segments) were calculated
at rest and at stress. CFR was calculated as MBFstress/MBFrest [17]., Coronary flow velocity reserve and inflammatory markers in living
6/j.ijcard.2020.08.013
Table 1
Demographic, laboratory and haemodynamic variables.
Controls (n = 25) Donors (n = 23) p value
Demographics
Age (years) 41 ± 10 46 ± 10 0.098
Male n(%) 18 (72) 16 (70) 0.853
Caucasian n(%) 15 (60) 18 (78) 0.173
BMI (kg/m2) 25.6 ± 2.3 26.8 ± 4.2 0.230
Smoker n(%) – Current 2 (8) 3 (13) 0.905
Ex 5 (20) 4 (17)
Never 18 (72) 16 (70)
Hypertension n(%) 1 (4) 1 (4) 1.0
Hypercholesterolaemia n(%) 8 (32) 13 (57) 0.145
ACE inhibitors n(%) 0 (0) 1 (4) 0.479
Statin therapy n(%) 2 (8) 1 (4) 1.0
Time from donation (months) n/a 30 (24–67) n/a
Laboratory data
Haemoglobin (g/l) 146 ± 11 141 ± 10 0.198
Urea (mmol/l) 5.0 ± 1.3 5.7 ± 1.1 0.061
Creatinine (μmol/l) 80 ± 17 107 ± 15 <0.001
eGFR (ml/min/1.73m2) 99 (91–112) 68 (64–72) <0.001
ACR (mg/mmol) 0.9 (0–2.1) 0.9 (0–1.8) 0.298
Phosphate (mmol/l) 1.13 ± 0.17 1.03 ± 0.17 0.042
Corrected calcium (mmol/l) 2.33 ± 0.08 2.36 ± 0.08 0.152
PTH (μmol/l) 5.7 ± 2.1 6.6 ± 2.0 0.237
Total cholesterol (mmol/l) 4.6 (4.0–5.2) 5.1 (4.8–5.6) 0.06
LDL cholesterol (mmol/l) 2.7 ± 1.0 3.2 ± 0.8 0.06
NT-proBNP (ng/l) 40 (22–69) 54 (24–95) 0.391
Detectable CRP n(%) 7 (29) 18 (73) 0.01
hsCRP (mg/l) 0.63 (0.41–0.86) 1.31 (0.92–2.0) 0.006
Urate (μmol/l) 332 ± 84 366 ± 82 0.158
Renin (mIU/l) 21.2 (16.9–35.6) 17.9 (13.4–35.5) 0.324
Aldosterone (μmol/l) 161 (129–225) 129 (44–222) 0.156
Haemodynamic data
Systolic BP (mmHg) 116 ± 11 115 ± 12 0.835
Diastolic BP (mmHg) 76 ± 10 76 ± 10 0.816
Heart rate (bpm) 71 ± 12 65 ± 11 0.066
Data are presented as mean ± SD or median (IQR). BMI – body mass index, ACE – angio-
tensin converting enzyme, eGFR – estimated glomerularfiltration rate, ACR – albumin cre-
atinine ratio, PTH – parathyroid hormone, LDL – low density lipoprotein, NT-proBNP – n
terminal pro brain natriuretic peptide, CRP – C reactive peptide, hsCRP – high sensitivity
C reactive peptide, BP – blood pressure.
3A. Radhakrishnan et al. / International Journal of Cardiology xxx (2020) xxx2.7. Blinded analysis
Echocardiograms were stored under an anonymous code and
analysed offline using commercially available software (IntelliSpace
Cardiovascular, Philips, Eindhoven, Netherlands). The TTE, CFVR and
MCE studies were all analysed by a single investigator (AR) blinded
to study group. Ten randomly selected studies had repeat blinded
Doppler CFVR analysis by the same investigator to assess intra-
observer variability.
2.8. Serum biomarkers
Serum biomarkers of inflammation, myocardial stretch, cardiac fi-
brosis and markers associated with left ventricular hypertrophy (LVH)
were tested in both LKD and controls. N-terminal pro brain natriuretic
peptide was assayed using the Alere point of care assay (Alere, Massa-
chusetts, USA). High sensitivity C-reactive peptide (hsCRP)was assayed
using the Architect MULTIGENT CRP Vario assay (Abbott, Illinois, USA).
The fluorescence responses of 16-analytes were obtained using Human
Magnetic Luminex® Asssays (R&D Systems, Minneapolis, MN, USA) and
the Bio-RAD Bio-Plex™ 200 system for analysis. Concentrations were cal-
culated using the Bio-Plex Software Manager™ (version 6.1) generated
standard curves and a 5PL logistic curve fitting technique as per theman-
ufacturer's instructions [21].
2.9. Endpoints & sample size justification
The primary endpoint was difference in mean Doppler CFVR be-
tween controls and LKD. Based on previous data by Imamura et al [10]
[CFVR for controls (3.8 ± 0.4), CFVR for CKD stage 2 (3.2 ± 0.7), CFVR
for CKD stage 3 (3.0 ± 0.6)] - we estimated that 22 patients in each
group would provide 80% power with an alpha value of 0.05 to demon-
strate a difference inDoppler CFVR of 0.6 between controls and LKD.Dif-
ference in CFR by MCE was the secondary endpoint.
2.10. Statistical analysis
Statistical analysis was carried out using SPSS version 26 (SPSS Inc.,
Chicago, Illinois). Data normality was assessed using the Shapiro-Wilk
test. Continuous variables are expressed as mean ± standard deviation
(SD) for parametric data or median (interquartile range) for non-
parametric data. Unpaired group comparisons for continuous data
were made using the unpaired t-test or the Mann-Whitney U test. Un-
paired categorical datawere compared using Fisher's exact test. Correla-
tion was assessed using the Pearson correlation coefficient. Statistical




Baseline demographic, laboratory and haemodynamic data are pre-
sented in Table 1. Median time from donation in LKD was 30 months
(interquartile range 24–67 months). There were no significant differ-
ences in demographic variables between controls and LKD. One LKD
was on anti-hypertensive therapy. Two controls and 1 LKD were on
statin therapy. Of the remaining 18 participants with total cholesterol
>5mmol/L, only 1 LKD and 2 controls met UK criteria for primary pre-
vention statin therapy (QRISK3 10 year risk >10%) [22].
There was a significant difference in creatinine and eGFR between
controls and donors. 3/23 (13%) donors had eGFR consistent with
stage 3 CKD while the remainder had eGFR in the range of CKD stage
2. Serum phosphate was significantly lower in LKD. Detectable C reac-
tive peptide (CRP) and median high sensitivity C reactive peptide
(hsCRP) were both significantly higher in LKD.Please cite this article as: A. Radhakrishnan, A.M. Price, L.C. Pickup, et al.
kidney donors, International Journal of Cardiology, https://doi.org/10.101There were no significant differences in TTE parameters be-
tween controls and LKD - Table 2. One individual had previously
undiagnosed severe aortic regurgitation detected on baseline TTE.
Markers of systolic and diastolic function were similar between
the two groups.3.2. Doppler coronary flow velocity reserve
Doppler CFVR was not attempted in the subject with severe aortic
regurgitation on baseline TTE. The technique was feasible in 46/47
(99%) of subjects inwhich itwas attempted. One subject did not tolerate
adenosine and thus no hyperaemic measurements were available. One
subject was subsequently excluded from CFVR analysis due to the new
finding of thyrotoxicosis on serum biochemistry. Final Doppler TTE
CFVR data were available in 22 controls and 23 LKD. SonoVue was
used in 31/45 (69%) cases. There was no significant intra-observer var-
iability for offline Doppler CFVR analysis (ICC 0.99 95% confidence inter-
val 0.956–0.998, p < .001).
Resting CFV in donors was slightly higher than in controls, al-
though this was not statistically significant [median CFV 19.9
(17.4–22.2) vs 18.1 (15.6–20.4), p = .114]. Hyperaemic CFV did
not differ (mean CFV 70.2 ± 14.6 vs 70.5 ± 13.8, p = .944) –
Fig. 1a. CFVR was significantly reduced in LKD compared to controls
(mean CFVR 3.4 ± 0.7 vs 3.8 ± 0.6, mean difference 0.4 95% confi-
dence interval 0.03–0.8, p = .036) – Fig. 1b. Although no subjects
in our study had CFVR<2, 6/23 (26%) LKD had CFVR ≤2.7 (the lowest
CFVR value in controls). There was a modest significant correlation









IVSD (mm) 10 (9–11) 10 (8–11) 0.106
LVIDD (mm) 44 ± 4 44 ± 5 0.946
PWD (mm) 9 (8–10) 9 (8–10) 0.732
LVIDS (mm) 28 ± 3 29 ± 4 0.470
Fractional Shortening (%) 36 (31–38) 32 (31–36) 0.201
LVEDVi (ml/m2) 46 ± 8 47 ± 10 0.716
LVESVi (ml/m2) 17 (14–19) 18 (13−22) 0.713
EF (%) 62 (60–65) 61 (57–65) 0.305
TAPSE (mm) 21 ± 3 20 ± 3 0.168
GLS (%) −19 ± 3 −19 ± 3 0.849
LV mass index (g/m2) 71 (62–88) 69 (57–76) 0.307
LV geometry n(%) – normal geometry 17 (68) 14 (61) 0.439
Concentric remodelling 6 (24) 9 (39)
Eccentric hypertrophy 1 (4)
Concentric hypertrophy 1 (4)
Left atrial volume index (ml/m2) 19.3 ± 4.3 20.5 ± 6.8 0.477
E/A ratio 1.2 ± 0.3 1.1 ± 0.2 0.184
E/e’ 6 (5–8) 6 (6–7) 0.655
Data are presented as mean ± SD or median (IQR). IVSD – interventricular septal di-
ameter, LVIDD – left ventricular internal diameter diastole, PWD – posterior wall di-
ameter, LVIDS – left ventricular internal diameter systole, LVEDVi – indexed left
ventricular end diastolic volume, LVESVi – indexed left ventricular end systolic vol-
ume, EF – ejection fraction, TAPSE – tricuspid annular plane systolic excursion,
GLS – global longitudinal strain, LV – left ventricular.
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No subjects had stress induced wall motion abnormalities or perfu-
sion defects on qualitative MCE. Quantitative MCE was possible in
only 14 controls and 19 LKD. Both LAD CFR and global CFRwere numer-
ically lower in LKD, although this was not statistically significant – LAD
CFR [median CFR 3.4 (2.6–5.0) vs 2.7 (2.2–3.9), p= .212] and global CFR
[median CFR 3.4 (2.2–3.8) vs 3.0 (2.3–4.2), p = 1.0].
3.4. Multiplex immunoassay
The results of theMultiplex immunoassay are shown in Table 3. One
control did not provide blood for immunoassay analysis. There were no
significant differences between controls and LKD in the assays tested,
apart from uromodulin which was significantly lower in LKD.
4. Discussion
This is the first study of CFVR in LKD. Despite only modest reduc-
tions in eGFR, LKD had a significantly lower Doppler CFVR than con-
trols. These results suggest that reductions in renal function alone
can lead to altered microvascular function. Reassuringly, no subjects
in our cohort had CFVR<2, which is known to be a poor prognostic
marker [13].
Previous studies using Doppler TTE have shown intra-subject varia-
tions in CFVR of 0.3–0.45 [15,23]. Given that the difference in CFVR be-
tween controls and LKD in our study was similar to this value, we
cannot fully exclude the possibility that this difference was due to
chance. However, our sample size was adequate and we would expect
similar variability of CFVR measurements in both groups. Furthermore,
the magnitude of difference between our controls and LKD is similar
to the previously demonstrated difference between controls and sub-
jects with CKD stage 2 – a group that have similar renal function to
LKD [10].
The wider variances in CFR by MCE among our subjects suggest that
our study may have been underpowered for this secondary endpoint.
Adenosine can cause uncomfortable dyspnoea and chest wall move-
ment that compromises the image quality needed for optimal MCE
quantification. Previous studies have used intravenous dipyridamole
[17], which has fewer respiratory side effects, but was not available inPlease cite this article as: A. Radhakrishnan, A.M. Price, L.C. Pickup, et al.
kidney donors, International Journal of Cardiology, https://doi.org/10.101our hospital. Coronary flow reserve by MCE was measurable in 69% of
our cohort, which is consistent with previous studies showing that
quantitative MCE using adenosine is feasible in only 33–75% of patients
[24,25]. Despite these limitations, ourMCEdata showed a trend towards
reduced CFR in LKD, which is consistent with our Doppler CFVR data.
We choseDoppler CFVR as our primary endpoint as the technique is fea-
sible and highly reproducible even with limited image quality [15].
The mechanisms of microvascular dysfunction in LKD are not
clear but abnormalities of both structure and function may be pres-
ent. Animal models have demonstrated reduced capillary length
and density in the hearts of rats who underwent subtotal nephrec-
tomy and evidence of fibrosis and diastolic dysfunction in rats after
uni-nephrectomy [26,27].
The reduced CFVR among LKD in our study was predominantly due
to a higher baseline CFV in LKD, with similar maximal hyperaemic
values. Elevated resting CFV is seen in CKD and hypertension and has
been attributed to increased oxygen demand as a result of hypertension,
LVH and diastolic dysfunction [10,28]. Elevated resting CFVmay also be
related to increased sympathetic nervous system (SNS) activity which
causes vasoconstriction of vascular smooth muscle cells, leading to in-
creased coronary vascular resistance and a decrease in coronary perfu-
sion pressure [29]. Increased SNS activity is seen in early CKD but has
not been studied in LKD [30]. In addition, the reduced CFVR in LKD
also reflects a diminished hyperaemic response to adenosine, indicating
impaired vasodilatation in the coronarymicrocirculation,where adeno-
sine predominantly has its effect [31]. Adenosine-induced vasodilata-
tion is at least partially mediated by nitric oxide release from the
endothelium [32], suggesting that endothelial dysfunction may be a
contributory mechanism for CMD in LKD. Studies in early CKD have
shown that endothelial dysfunction is common and is associated with
poor prognosis [33,34]. To date, there are no studies of endothelial func-
tion in LKD but the CENS study, which is currently recruiting, will pro-
vide a comprehensive assessment of endothelial function in LKD [35].
Chronic inflammation in systemic inflammatory conditions is associ-
ated with CMD [36]. Both detectable CRP and mean hsCRP were signif-
icantly higher in LKD. An inflammatory response has been shown in the
early post-operative period in LKDwith an80-fold increase in CRP in the
first week after nephrectomy [37]. Longer term data on chronic inflam-
mation in LKD are conflicting. Huan et al showed no increase in inflam-
matory markers in LKD at 6 months post donation [38]. However,
Moody et al showed an increase in the prevalence of detectable CRP in
LKD at 12 months post donation [4]. The elevated hsCRP suggests that
a pattern of subclinical chronic inflammation may be present in LKD,
as it is in subjects with CKD [39]. Uromodulin, a glycoprotein secreted
by the thick ascending limb of the loop of Henle, may play a role in
this process. In a normally functioning kidney, uromodulin may have a
protective anti-inflammatory role through neutralisation of urinary cy-
tokines. As renal function declines, so does uromodulin. In the presence
of tubular damage, as seen in CKD, the reduction in uromodulin may
have a pro-inflammatory effect by activating NLRP3 dependent IL-1β
secretion and subsequent induction of other pro-inflammatory cyto-
kines [40]. It is possible that the raised CRP, hsCRP and uromodulin in
LKD were chance findings due to the large number of variables tested.
After adjustment with a Bonferroni correction for multiple endpoints,
they fail to reach statistical significance. However, this correction has
been subject to criticism [41], and as CKD is characterised by systemic
inflammation, there are plausible reasons why subjects with reduced
kidney function due to uni-nephrectomy might also exhibit a pro-
inflammatory state. The role of inflammation after nephrectomy war-
rants further research.
The clinical significance of ourfindings needs further investigation. It
is possible that this small reduction in coronary microvascular function
in LKD may not have clinical sequelae and is an epi-phenomenon re-
lated to persistent low-grade inflammation after uni-nephrectomy.
However, there is increasing evidence of a possible role for CMD in the
development of heart failure with preserved ejection fraction and, Coronary flow velocity reserve and inflammatory markers in living
6/j.ijcard.2020.08.013
Fig. 1. 1a – Coronary flow velocity at rest and at hyperaemia in controls and living kidney donors. 1b – Doppler coronary flow velocity reserve in controls and living kidney donors. Squares
represent mean. Error bars represent 95% confidence intervals. Circles represent individual CFVR measurements. CFV – coronary flow velocity, CFVR – coronary flow velocity reserve.
Table 3
Results of human magnetic luminex assay.













Detectable IL-10 n(%) 11 (44) 11 (48) 0.790
Detectable KIM-1 n(%) 9 (36) 11 (48) 0.406
Galectin-3 (ng/ml) 0.9 (0.8–1.2) 1.1 (0.8–1.3) 0.317
IL-1ra (pg/ml) 522 (356–655) 503 (340–703) 0.807
IL-6 (pg/ml) 1.26 (0.82–1.86) 1.26 (0.97–1.81) 0.661
IL-8 (pg/ml) 12.3 (8.4–25.5) 11.3 (8–29.1) 0.992
Leptin (ng/ml) 5.7 (3.0–11.1) 4.9 (3.2–8.5) 0.865






NGAL (ng/ml) 15.5 (14.0–16.6) 16.7 (14.4–18.3) 0.187
ST2 (ng/ml) 12 (9–16) 10 (6–18) 0.444
TNFα (pg/ml) 3.5 (2.53–4.22) 3.37 (2.59–4.28) 0.924
Uromodulin (ng/ml) 98 ± 43 67 ± 35 0.009
VEGF (pg/ml) 48 (24–60) 65 (41–93) 0.101
Data are presented as mean± SD ormedian (IQR). IL-10 – interleukin-10, KIM-1 – kidney
injurymolecule 1, IL-1ra – interleukin 1 receptor antagonist, IL-6 – interleukin-6, IL-8 – in-
terleukin-8, MCP-1 –monocyte chemoattractant protein, MMP-9 –matrix metallopeptidase
9, NGAL – neutrophil gelatinase associated lipocalin, TNFα – tumour necrosis factor alpha,
VEGF – vascular endothelial growth factor.
5A. Radhakrishnan et al. / International Journal of Cardiology xxx (2020) xxxuraemic cardiomyopathy [9]. In CKD, the presence of CMD is associated
with abnormalities of diastolic function and indices of systolic deforma-
tion, as well as adverse cardiovascular outcomes including death, myo-
cardial infarction and heart failure hospitalisation [14]. Thus, a paradigm
has been suggested in which risk factors such as inflammation and hy-
pertension lead to CMD, which in turn causes diffuse ischaemia and ad-
verse left ventricular re-modelling, leading eventually to uraemic
cardiomyopathywith its adverse prognosis [9]. Our results should stim-
ulate long term studies of LKD to determine their subsequent risk of the
development of diastolic dysfunction, adverse left ventricular remodelling
and uraemic cardiomyopathy. As long-term cardiovascular risk in LKD re-
mains unclear and CMD carries a poor prognosis, baseline assessment ofPlease cite this article as: A. Radhakrishnan, A.M. Price, L.C. Pickup, et al.
kidney donors, International Journal of Cardiology, https://doi.org/10.101coronary microvascular function may be worthwhile in potential kidney
donors, to help identify individuals who are at increased cardiac risk
from kidney donation.5. Limitations
Similar to other non-invasive studies of CFVR, we could not fully ex-
clude coronary artery disease (CAD) in our cohort without coronary an-
giography (either computed tomography or invasive). However, all
subjects had normal ECG and no coronary distribution perfusion defect
or regional wall motion abnormality on vasodilator MCE – a highly sen-
sitive and specific technique for the diagnosis of flow limiting CAD [42].
Thus we have strong evidence that there was no myocardial ischemia
due to CAD in our cohort.
Our cohort was predominantly male and Caucasian, limiting the
generalisability of our findings to the wider LKD population. However,
UK data does show that the majority of LKD are Caucasian [2], and it
has previously been shown that there are similar rates of CMD among
men and women [43].
Finally, our study was cross-sectional in design, meaning that causa-
tion cannot be definitively demonstrated. Future longitudinal work ex-
amining CFVR pre- and post-nephrectomy is needed to confirm the
observation seen in our study.6. Conclusions
Our study has shown that Doppler CFVR is reduced in LKD compared
to healthy controls, suggesting subclinical impairment of microvascular
function. Although current data suggests that living kidney donation re-
mains extremely safe, our study highlights the importance of long-term
follow-up and aggressive risk factor management to detect subtle car-
diovascular changes and tominimise any future cardiovascularmorbid-
ity andmortality in this population. The role of chronic inflammation in
LKD also needs further examination.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2020.08.013., Coronary flow velocity reserve and inflammatory markers in living
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